Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Fair Value of Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

EMERGENT BIOSOLUTIONS INC. Fair Value of Long-Term Debt

EMERGENT BIOSOLUTIONS INC. (EBS) had Fair Value of Long-Term Debt of $62.80 million as of 2012-12-31, per its 10-K filed 2013-03-08.

Discontinued › Notes › Debt › Debt Instruments

us-gaap:LongTermDebtFairValue · last filed 2013-03-08

  • 2012-12-31: Long-term Debt, Fair Value $62.80M.
  • 2012-09-30: Long-term Debt, Fair Value $63.01M.
  • 2012-06-30: Long-term Debt, Fair Value $62.20M.
  • 2011-12-31: Long-term Debt, Fair Value $59.50M.
Period endLong-term Debt, Fair Value
2012-12-31$62.80M
10-K · filed 2013-03-08
2012-09-30$63.01M
10-Q · filed 2012-11-01
2012-06-30$62.20M
10-Q · filed 2012-08-03
2011-12-31$59.50M
10-K · filed 2013-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45